Business
Spero Therapeutics Announces Closing of Rights Offering
CAMBRIDGE, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on
About this update from Spero Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the closing of its previously announced rights offering (the “Rights Offering”). At the closing, Spero sold and issued an aggregate of 1,046,249 shares of its common stock (the “Common Stock”) and an aggregate of 2,287 shares of its Series C convertible preferred stock (“Series C Preferred Stock”) pursuant to the exercise of subscription rights and oversubscription rights in the Rights Offering by existing holders of its Common Stock, Series A convertible preferred stock and Series B convertible preferred stock. Certain affiliates of BVF Partners L.P., a Spero stockholder, were the sole purchasers of the shares of Series C Preferred Stock sold in the Rights Offering pursuant to the exercise of their subscription and oversubscription rights. Spero raised aggregate gross proceeds of approximately $30.0 million in the Rights Offering.\n The Rights Offering was made pursuant to Spero’s effective shelf registration statement on file with the Securities and Exchange Commission (the “SEC”) (File No. 333-228661) and a prospectus supplement and accompanying prospectus filed with the SEC on February 11, 2020. About SperoSpero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections and rare diseases. Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of rare, orphan disease caused by pulmonary non-tuberculous mycobacterial (NTM) infections. Spero also has a platform technology known as its Potentiator Platform that includes an IV-administered product candidate, SPR206, being developed to treat MDR Gram-negative infections in the hospital setting. For more information, visit https://sperotherapeutics.com. Forward Lookin...